ArticleCancers2025

CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia.

Margery Gang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.